<DOC>
	<DOC>NCT01376193</DOC>
	<brief_summary>The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.</brief_summary>
	<brief_title>Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naratriptan</mesh_term>
	<criteria>Subjects with migraine headache Must use naratriptan tablets for the first time Subjects with hypersensitivity to naratriptan Subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina Subjects with history of peripheral vascular disorder Subjects with history of cerebrovascular disorder or transient ischemic attacks Subjects with uncontrolled highblood pressure Subjects with severe hepatic function disorder or renal function disorder Subjects taking ergotamine, ergotamine derivative containing product, or 5HT1B/1D agonist</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>